Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Declines By 19.4%

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the target of a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 4,289 shares, a decrease of 19.4% from the January 29th total of 5,320 shares. Based on an average daily trading volume, of 22,585 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 22,585 shares, the short-interest ratio is presently 0.2 days.

Jasper Therapeutics Stock Performance

JSPRW remained flat at $0.02 during trading on Thursday. 8,485 shares of the company’s stock were exchanged, compared to its average volume of 26,244. The firm has a fifty day moving average of $0.04 and a two-hundred day moving average of $0.08. Jasper Therapeutics has a 12-month low of $0.02 and a 12-month high of $0.18.

About Jasper Therapeutics

Jasper Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on developing a new generation of cellular therapeutics for severe diseases. The company’s mission centers on harnessing targeted biological agents and engineered cell platforms to improve outcomes in hematopoietic stem cell transplantation, oncology and gene therapies. By advancing novel approaches to conditioning regimens and cell engineering, Jasper aims to address limitations of existing treatments, including toxicity, graft failure and restricted applicability.

The company’s lead candidate, JSP191, is a humanized monoclonal antibody targeting the CD117 receptor on hematopoietic stem cells.